Thyrocare Reports Q4 FY26 Audited Results with Unmodified Opinion
Thyrocare Technologies Limited announced audited standalone and consolidated results for Q4 FY26. Standalone revenue was ₹210.67 crore and PAT ₹43.58 crore. Consolidated revenue was ₹223.95 crore and PAT ₹41.98 crore. The board recommended a ₹7 per share final dividend.
The announcement provides audited financial results for the quarter and year-end, including key financial metrics and a dividend recommendation. This information is material for investors to assess the company's performance and future prospects.
The announcement reports financial results and an unmodified audit opinion, which are standard disclosures. While the results themselves might be positive or negative, the announcement itself is factual and does not contain overtly positive or negative language beyond the financial figures.
Thyrocare Technologies Limited has announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board Meeting, where these results were approved, commenced at 3:35 PM and concluded at 5:40 PM on May 7, 2026.
The company's statutory auditors, M/s. M S K A & Associates LLP, have issued an unmodified opinion on these financial results. A declaration from the Chief Financial Officer confirming the unmodified opinion is also enclosed. The detailed financial results and the auditors' report are available on the company's website.
For the standalone results, revenue from operations for the quarter ended March 31, 2026, stood at ₹210.67 crore, with a profit after tax of ₹43.58 crore. For the full financial year, revenue from operations was ₹774.27 crore, and profit after tax was ₹148.81 crore.
The consolidated results show revenue from operations for the quarter ended March 31, 2026, at ₹223.95 crore, with a profit after tax of ₹41.98 crore. For the full financial year, revenue from operations was ₹829.04 crore, and profit after tax was ₹143.57 crore.
The Board of Directors has recommended a final dividend of ₹7 per equity share, subject to shareholder approval at the upcoming meeting.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.